If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> ONCOLOGY<br /> ISSN 2054-619X Vol 4.1 • November 2016 • emjreviews.com<br /> INSIDE<br /> Review of<br /> ESMO 2016<br /> Copenhagen, Denmark<br /> CONTENTS<br /> EDITORIAL BOARD...................................................................................................................................... 7<br /> CONGRESS REVIEW.................................................................................................................................... 14<br /> • Review of the European Society of Medical Oncology (ESMO) Congress,<br /> held in Copenhagen, Denmark, 7th–11th October 2016<br /> INTERVIEWS.................................................................................................................................................. 34<br /> SYMPOSIUM REVIEWS<br /> • STATE-OF-THE-ART INTEGRATION OF MULTIPLE KINASE INHIBITORS IN THE<br /> TREATMENT OF GASTROINT<a title="EMJ Oncology 4.1 2016 page 1" href="http://viewer.zmags.com/publication/f4759b38?page=1"> ONCOLOGY ISSN 2054-619X </a> <a title="EMJ Oncology 4.1 2016 page 2" href="http://viewer.zmags.com/publication/f4759b38?page=2"> CONTENTS EDITORIAL BOARD.......................</a> <a title="EMJ Oncology 4.1 2016 page 3" href="http://viewer.zmags.com/publication/f4759b38?page=3"> ONCOLOGY • THE IMPORTANCE OF MUTATIONAL ANALY</a> <a title="EMJ Oncology 4.1 2016 page 4" href="http://viewer.zmags.com/publication/f4759b38?page=4"> Novartis Pharma AG CH-4002 Basel Switzerland </a> <a title="EMJ Oncology 4.1 2016 page 5" href="http://viewer.zmags.com/publication/f4759b38?page=5"> AML is swarming with challenges Strikingly heter</a> <a title="EMJ Oncology 4.1 2016 page 6" href="http://viewer.zmags.com/publication/f4759b38?page=6"> See how you can guide the path her cancer takes </a> <a title="EMJ Oncology 4.1 2016 page 7" href="http://viewer.zmags.com/publication/f4759b38?page=7"> Editorial Board Editor-in-Chief: Dr Ahmad Awada</a> <a title="EMJ Oncology 4.1 2016 page 8" href="http://viewer.zmags.com/publication/f4759b38?page=8"> ONCOLOGY 4.1 NOVEMBER 2016 Director Spencer Gor</a> <a title="EMJ Oncology 4.1 2016 page 9" href="http://viewer.zmags.com/publication/f4759b38?page=9"> Welcome Welcome to the latest edition of EMJ O</a> <a title="EMJ Oncology 4.1 2016 page 10" href="http://viewer.zmags.com/publication/f4759b38?page=10"> 10 If you are interested in submitting a paper</a> <a title="EMJ Oncology 4.1 2016 page 11" href="http://viewer.zmags.com/publication/f4759b38?page=11"> Foreword </a> <a title="EMJ Oncology 4.1 2016 page 12" href="http://viewer.zmags.com/publication/f4759b38?page=12"> NOW APPROVED </a> <a title="EMJ Oncology 4.1 2016 page 13" href="http://viewer.zmags.com/publication/f4759b38?page=13"> ✔✔✔ OS1 PFS1 ORR1 “CABOMETYX® is </a> <a title="EMJ Oncology 4.1 2016 page 14" href="http://viewer.zmags.com/publication/f4759b38?page=14"> 14 ONCOLOGY • November 2016 </a> <a title="EMJ Oncology 4.1 2016 page 15" href="http://viewer.zmags.com/publication/f4759b38?page=15"> ONCOLOGY • November 2016 </a> <a title="EMJ Oncology 4.1 2016 page 16" href="http://viewer.zmags.com/publication/f4759b38?page=16"> 16 ONCOLOGY • November 2016 </a> <a title="EMJ Oncology 4.1 2016 page 17" href="http://viewer.zmags.com/publication/f4759b38?page=17"> Congress Highlights ESMO-MCBS: A Qua</a> <a title="EMJ Oncology 4.1 2016 page 18" href="http://viewer.zmags.com/publication/f4759b38?page=18"> ESMO-MCBS online to analyse what can be expected </a> <a title="EMJ Oncology 4.1 2016 page 19" href="http://viewer.zmags.com/publication/f4759b38?page=19"> patients suffering from metastatic or locally adv</a> <a title="EMJ Oncology 4.1 2016 page 20" href="http://viewer.zmags.com/publication/f4759b38?page=20"> Copenhagen “Toxicities of targeted </a> <a title="EMJ Oncology 4.1 2016 page 21" href="http://viewer.zmags.com/publication/f4759b38?page=21"> Clinical researchers must develop new solutions t</a> <a title="EMJ Oncology 4.1 2016 page 22" href="http://viewer.zmags.com/publication/f4759b38?page=22"> With melanoma rates in Europe at 1 in 100 people </a> <a title="EMJ Oncology 4.1 2016 page 23" href="http://viewer.zmags.com/publication/f4759b38?page=23"> Currently the side effects of radiation</a> <a title="EMJ Oncology 4.1 2016 page 24" href="http://viewer.zmags.com/publication/f4759b38?page=24"> Nonetheless, the strict inclusion criteri</a> <a title="EMJ Oncology 4.1 2016 page 25" href="http://viewer.zmags.com/publication/f4759b38?page=25"> with a germline BRCA mutation. Outside of the EU,</a> <a title="EMJ Oncology 4.1 2016 page 26" href="http://viewer.zmags.com/publication/f4759b38?page=26"> specific symptoms and overall health status, with </a> <a title="EMJ Oncology 4.1 2016 page 27" href="http://viewer.zmags.com/publication/f4759b38?page=27"> Pembrolizumab with First-Line Chemotherapy Signifi</a> <a title="EMJ Oncology 4.1 2016 page 28" href="http://viewer.zmags.com/publication/f4759b38?page=28"> an independent central review committee of r</a> <a title="EMJ Oncology 4.1 2016 page 29" href="http://viewer.zmags.com/publication/f4759b38?page=29"> Metastatic Renal Cell Carcinoma Patient Survival </a> <a title="EMJ Oncology 4.1 2016 page 30" href="http://viewer.zmags.com/publication/f4759b38?page=30"> In this 80% of patients who have a high-risk soft</a> <a title="EMJ Oncology 4.1 2016 page 31" href="http://viewer.zmags.com/publication/f4759b38?page=31"> completed the subsequent questionnaire and was as</a> <a title="EMJ Oncology 4.1 2016 page 32" href="http://viewer.zmags.com/publication/f4759b38?page=32"> ESMO Calls for Improved Participation in Cancer S</a> <a title="EMJ Oncology 4.1 2016 page 33" href="http://viewer.zmags.com/publication/f4759b38?page=33"> Squamous cell carcinoma of the head and neck (SCC</a> <a title="EMJ Oncology 4.1 2016 page 34" href="http://viewer.zmags.com/publication/f4759b38?page=34"> Paolo Bossi Head and Neck Unit, Fondazione IRCCS</a> <a title="EMJ Oncology 4.1 2016 page 35" href="http://viewer.zmags.com/publication/f4759b38?page=35"> which of the toxicities are more troublesome to t</a> <a title="EMJ Oncology 4.1 2016 page 36" href="http://viewer.zmags.com/publication/f4759b38?page=36"> that patients take correctly their pills … becaus</a> <a title="EMJ Oncology 4.1 2016 page 37" href="http://viewer.zmags.com/publication/f4759b38?page=37"> Exclusive Interviews from the European Societ</a> <a title="EMJ Oncology 4.1 2016 page 38" href="http://viewer.zmags.com/publication/f4759b38?page=38"> STATE-OF-THE-ART INTEGRATION OF MULTIPLE KINA</a> <a title="EMJ Oncology 4.1 2016 page 39" href="http://viewer.zmags.com/publication/f4759b38?page=39"> real-world experience since regorafenib received </a> <a title="EMJ Oncology 4.1 2016 page 40" href="http://viewer.zmags.com/publication/f4759b38?page=40"> Interestingly, the lower hazard ratios (HRs)</a> <a title="EMJ Oncology 4.1 2016 page 41" href="http://viewer.zmags.com/publication/f4759b38?page=41"> regorafenib is recommended so that therapy can be</a> <a title="EMJ Oncology 4.1 2016 page 42" href="http://viewer.zmags.com/publication/f4759b38?page=42"> was that the activity of regorafenib was similar </a> <a title="EMJ Oncology 4.1 2016 page 43" href="http://viewer.zmags.com/publication/f4759b38?page=43"> Likewise, regorafenib may offer a poten</a> <a title="EMJ Oncology 4.1 2016 page 44" href="http://viewer.zmags.com/publication/f4759b38?page=44"> patients with HCC who progressed following s</a> <a title="EMJ Oncology 4.1 2016 page 45" href="http://viewer.zmags.com/publication/f4759b38?page=45"> Cancer Subtyping Consortium (CRCSC) identification</a> <a title="EMJ Oncology 4.1 2016 page 46" href="http://viewer.zmags.com/publication/f4759b38?page=46"> double-blind, placebo-controlled trial. Lance</a> <a title="EMJ Oncology 4.1 2016 page 47" href="http://viewer.zmags.com/publication/f4759b38?page=47"> OPTIMISING SALVAGE THERAPY IN AGGRESSIVE </a> <a title="EMJ Oncology 4.1 2016 page 48" href="http://viewer.zmags.com/publication/f4759b38?page=48"> guidelines such as the European Society of Medica</a> <a title="EMJ Oncology 4.1 2016 page 49" href="http://viewer.zmags.com/publication/f4759b38?page=49"> Treatment Algorithm for Aggressive Non-Hodgkin Ly</a> <a title="EMJ Oncology 4.1 2016 page 50" href="http://viewer.zmags.com/publication/f4759b38?page=50"> Relapsed/Refractory Aggressive B Cell Non-Hodgkin</a> <a title="EMJ Oncology 4.1 2016 page 51" href="http://viewer.zmags.com/publication/f4759b38?page=51"> role of ibrutinib as a single agent, parti</a> <a title="EMJ Oncology 4.1 2016 page 52" href="http://viewer.zmags.com/publication/f4759b38?page=52"> Table 2: Response rates of relapsed or refractory</a> <a title="EMJ Oncology 4.1 2016 page 53" href="http://viewer.zmags.com/publication/f4759b38?page=53"> Prof Zinzani replied that there were no data so f</a> <a title="EMJ Oncology 4.1 2016 page 54" href="http://viewer.zmags.com/publication/f4759b38?page=54"> REFERENCES 1. European Medicines Agency. EPA</a> <a title="EMJ Oncology 4.1 2016 page 55" href="http://viewer.zmags.com/publication/f4759b38?page=55"> (PSHAP) in relapsed/refractory aggres</a> <a title="EMJ Oncology 4.1 2016 page 56" href="http://viewer.zmags.com/publication/f4759b38?page=56"> CABOZANTINIB AS FIRST-LINE THERAPY FOR PATIENTS </a> <a title="EMJ Oncology 4.1 2016 page 57" href="http://viewer.zmags.com/publication/f4759b38?page=57"> because, unlike previous studies, the trial </a> <a title="EMJ Oncology 4.1 2016 page 58" href="http://viewer.zmags.com/publication/f4759b38?page=58"> 1.0 Progression-free survival (probability) 0.8</a> <a title="EMJ Oncology 4.1 2016 page 59" href="http://viewer.zmags.com/publication/f4759b38?page=59"> Additionally, cabozantinib treatment improves ORR</a> <a title="EMJ Oncology 4.1 2016 page 60" href="http://viewer.zmags.com/publication/f4759b38?page=60"> REGORAFENIB IN METASTATIC COLORECTAL CANCER </a> <a title="EMJ Oncology 4.1 2016 page 61" href="http://viewer.zmags.com/publication/f4759b38?page=61"> Introduction Regorafenib is an oral mult</a> <a title="EMJ Oncology 4.1 2016 page 62" href="http://viewer.zmags.com/publication/f4759b38?page=62"> <70 years and ≥70 years, median (95% CI) PFS was </a> <a title="EMJ Oncology 4.1 2016 page 63" href="http://viewer.zmags.com/publication/f4759b38?page=63"> Regorafenib Dose Optimisation Study in Refractory</a> <a title="EMJ Oncology 4.1 2016 page 64" href="http://viewer.zmags.com/publication/f4759b38?page=64"> In the final analysis, baseline characteristics we</a> <a title="EMJ Oncology 4.1 2016 page 65" href="http://viewer.zmags.com/publication/f4759b38?page=65"> 5. Grothey A et al. Optimizing treatment outcomes</a> <a title="EMJ Oncology 4.1 2016 page 66" href="http://viewer.zmags.com/publication/f4759b38?page=66"> Abstract Reviews PROGRESSING G1-G2 WELL-DIFFE</a> <a title="EMJ Oncology 4.1 2016 page 67" href="http://viewer.zmags.com/publication/f4759b38?page=67"> ESMO 2016 progressive WDNET with acceptabl</a> <a title="EMJ Oncology 4.1 2016 page 68" href="http://viewer.zmags.com/publication/f4759b38?page=68"> Abstract Reviews correlated with a major disease</a> <a title="EMJ Oncology 4.1 2016 page 69" href="http://viewer.zmags.com/publication/f4759b38?page=69"> ESMO 2016 bone and/or lymph node metastases (n=2</a> <a title="EMJ Oncology 4.1 2016 page 70" href="http://viewer.zmags.com/publication/f4759b38?page=70"> Abstract Reviews pathological response. The r</a> <a title="EMJ Oncology 4.1 2016 page 71" href="http://viewer.zmags.com/publication/f4759b38?page=71"> ESMO 2016 alterations that would predict a lack </a> <a title="EMJ Oncology 4.1 2016 page 72" href="http://viewer.zmags.com/publication/f4759b38?page=72"> Abstract Reviews with a control. The RCTs involv</a> <a title="EMJ Oncology 4.1 2016 page 73" href="http://viewer.zmags.com/publication/f4759b38?page=73"> ESMO 2016 more likely to be Asian, Eastern </a> <a title="EMJ Oncology 4.1 2016 page 74" href="http://viewer.zmags.com/publication/f4759b38?page=74"> Abstract Reviews No trend to survival benefit was</a> <a title="EMJ Oncology 4.1 2016 page 75" href="http://viewer.zmags.com/publication/f4759b38?page=75"> ESMO 2016 Hermini Manzano,12 Carlos Horndler,13 M</a> <a title="EMJ Oncology 4.1 2016 page 76" href="http://viewer.zmags.com/publication/f4759b38?page=76"> Abstract Reviews (95% CI: 0.41–1.12). Adjusted h</a> <a title="EMJ Oncology 4.1 2016 page 77" href="http://viewer.zmags.com/publication/f4759b38?page=77"> Click here to view the AWARD WINNERS at the Eu</a> <a title="EMJ Oncology 4.1 2016 page 78" href="http://viewer.zmags.com/publication/f4759b38?page=78"> EDITOR’S PICK Paed</a> <a title="EMJ Oncology 4.1 2016 page 79" href="http://viewer.zmags.com/publication/f4759b38?page=79"> capacity deficits,4-8 and a markedly increased ris</a> <a title="EMJ Oncology 4.1 2016 page 80" href="http://viewer.zmags.com/publication/f4759b38?page=80"> and cell death. The disruption of the β-tub</a> <a title="EMJ Oncology 4.1 2016 page 81" href="http://viewer.zmags.com/publication/f4759b38?page=81"> significant insulin resistance, increased prot</a> <a title="EMJ Oncology 4.1 2016 page 82" href="http://viewer.zmags.com/publication/f4759b38?page=82"> Table 1: Childhood cancer treatments, mechanisms </a> <a title="EMJ Oncology 4.1 2016 page 83" href="http://viewer.zmags.com/publication/f4759b38?page=83"> Aerobic exercise to reverse mitochondrial dysfunc</a> <a title="EMJ Oncology 4.1 2016 page 84" href="http://viewer.zmags.com/publication/f4759b38?page=84"> factors in adult survivors of pediatric canc</a> <a title="EMJ Oncology 4.1 2016 page 85" href="http://viewer.zmags.com/publication/f4759b38?page=85"> children with leukemia. J Strength Cond Res. 2007</a> <a title="EMJ Oncology 4.1 2016 page 86" href="http://viewer.zmags.com/publication/f4759b38?page=86"> THE IMPORTANCE OF MUTATIONAL ANALYSIS IN CH</a> <a title="EMJ Oncology 4.1 2016 page 87" href="http://viewer.zmags.com/publication/f4759b38?page=87"> and spectacularly improve the disease burden</a> <a title="EMJ Oncology 4.1 2016 page 88" href="http://viewer.zmags.com/publication/f4759b38?page=88"> select for a compound mutant: the initial mutated</a> <a title="EMJ Oncology 4.1 2016 page 89" href="http://viewer.zmags.com/publication/f4759b38?page=89"> Table 1: Most common techniques for mutational an</a> <a title="EMJ Oncology 4.1 2016 page 90" href="http://viewer.zmags.com/publication/f4759b38?page=90"> Next-Generation Sequencing and Ultra-Deep Sequenc</a> <a title="EMJ Oncology 4.1 2016 page 91" href="http://viewer.zmags.com/publication/f4759b38?page=91"> B Frequency of patients (%) 50 45 40 35 30 25 2</a> <a title="EMJ Oncology 4.1 2016 page 92" href="http://viewer.zmags.com/publication/f4759b38?page=92"> relapse, or suboptimal response to first</a> <a title="EMJ Oncology 4.1 2016 page 93" href="http://viewer.zmags.com/publication/f4759b38?page=93"> available TKIs, with the exception of ponatinib.1</a> <a title="EMJ Oncology 4.1 2016 page 94" href="http://viewer.zmags.com/publication/f4759b38?page=94"> CONCLUSIONS BCR-ABL KD mutations may emerge at a</a> <a title="EMJ Oncology 4.1 2016 page 95" href="http://viewer.zmags.com/publication/f4759b38?page=95"> 32. Zabriskie MS et al. BCR-ABL1 compou</a> <a title="EMJ Oncology 4.1 2016 page 96" href="http://viewer.zmags.com/publication/f4759b38?page=96"> MODERN INDICATIONS FOR ENDOSCOPIC </a> <a title="EMJ Oncology 4.1 2016 page 97" href="http://viewer.zmags.com/publication/f4759b38?page=97"> and bleeding. The complication rate naturall</a> <a title="EMJ Oncology 4.1 2016 page 98" href="http://viewer.zmags.com/publication/f4759b38?page=98"> decompression remains controversial in whethe</a> <a title="EMJ Oncology 4.1 2016 page 99" href="http://viewer.zmags.com/publication/f4759b38?page=99"> 24–48 hours before surgery is recommended by most</a> <a title="EMJ Oncology 4.1 2016 page 100" href="http://viewer.zmags.com/publication/f4759b38?page=100"> endoscopic skull base surgery development. A</a> <a title="EMJ Oncology 4.1 2016 page 101" href="http://viewer.zmags.com/publication/f4759b38?page=101"> reached to treat cholesterol granuloma. Thos</a> <a title="EMJ Oncology 4.1 2016 page 102" href="http://viewer.zmags.com/publication/f4759b38?page=102"> 36. Hadad G et al. A novel reconstructive techniq</a> <a title="EMJ Oncology 4.1 2016 page 103" href="http://viewer.zmags.com/publication/f4759b38?page=103"> microRNAS IN THERAPY RESISTANCE O</a> <a title="EMJ Oncology 4.1 2016 page 104" href="http://viewer.zmags.com/publication/f4759b38?page=104"> HER2-enriched patients depends on expression </a> <a title="EMJ Oncology 4.1 2016 page 105" href="http://viewer.zmags.com/publication/f4759b38?page=105"> A Chemotherapeutic drugs Targeted HER2 the</a> <a title="EMJ Oncology 4.1 2016 page 106" href="http://viewer.zmags.com/publication/f4759b38?page=106"> Combinations of anthracyclines, such as doxorubic</a> <a title="EMJ Oncology 4.1 2016 page 107" href="http://viewer.zmags.com/publication/f4759b38?page=107"> A Tr miR-375 L N A miR-630 </a> <a title="EMJ Oncology 4.1 2016 page 108" href="http://viewer.zmags.com/publication/f4759b38?page=108"> In contrast, high levels of miR-144 enhance</a> <a title="EMJ Oncology 4.1 2016 page 109" href="http://viewer.zmags.com/publication/f4759b38?page=109"> The tumour-suppressive function of miR-200c n</a> <a title="EMJ Oncology 4.1 2016 page 110" href="http://viewer.zmags.com/publication/f4759b38?page=110"> are of particular interest in understanding </a> <a title="EMJ Oncology 4.1 2016 page 111" href="http://viewer.zmags.com/publication/f4759b38?page=111"> cancer resistance: A new molecular plot. Clin Pha</a> <a title="EMJ Oncology 4.1 2016 page 112" href="http://viewer.zmags.com/publication/f4759b38?page=112"> 70. Czerwinska P, Kaminska B. Regulation 71. S</a> <a title="EMJ Oncology 4.1 2016 page 113" href="http://viewer.zmags.com/publication/f4759b38?page=113"> GASTROINTESTINAL STROMAL TUMOURS: A REVIE</a> <a title="EMJ Oncology 4.1 2016 page 114" href="http://viewer.zmags.com/publication/f4759b38?page=114"> kinase (KIT) or platelet-derived growth fact</a> <a title="EMJ Oncology 4.1 2016 page 115" href="http://viewer.zmags.com/publication/f4759b38?page=115"> tumours exclusively occurring in the stomach.21,2</a> <a title="EMJ Oncology 4.1 2016 page 116" href="http://viewer.zmags.com/publication/f4759b38?page=116"> 24% of GISTs were locally advanced or metastatic,</a> <a title="EMJ Oncology 4.1 2016 page 117" href="http://viewer.zmags.com/publication/f4759b38?page=117"> INVESTIGATIONS Most GISTs are diagnosed either a</a> <a title="EMJ Oncology 4.1 2016 page 118" href="http://viewer.zmags.com/publication/f4759b38?page=118"> with an exception being exon 9 KIT mutations wher</a> <a title="EMJ Oncology 4.1 2016 page 119" href="http://viewer.zmags.com/publication/f4759b38?page=119"> Table 2: Key trials with tyrosine kinase inhibito</a> <a title="EMJ Oncology 4.1 2016 page 120" href="http://viewer.zmags.com/publication/f4759b38?page=120"> PROGNOSIS Recurrence rates and survival of </a> <a title="EMJ Oncology 4.1 2016 page 121" href="http://viewer.zmags.com/publication/f4759b38?page=121"> Pathol. 2007;31(11):1629-35. 32. Rossi S et</a> <a title="EMJ Oncology 4.1 2016 page 122" href="http://viewer.zmags.com/publication/f4759b38?page=122"> SOMATIC MUTATIONS IN MYELODYSPLASTIC SYNDROME P</a> <a title="EMJ Oncology 4.1 2016 page 123" href="http://viewer.zmags.com/publication/f4759b38?page=123"> Table 1: Most common somatic mutations in myelody</a> <a title="EMJ Oncology 4.1 2016 page 124" href="http://viewer.zmags.com/publication/f4759b38?page=124"> outcome after alloSCT.11 Due to the fact that MDS</a> <a title="EMJ Oncology 4.1 2016 page 125" href="http://viewer.zmags.com/publication/f4759b38?page=125"> the myeloid diseases.18,33 These genetic aberrati</a> <a title="EMJ Oncology 4.1 2016 page 126" href="http://viewer.zmags.com/publication/f4759b38?page=126"> high level of bone marrow blasts, donor type, and</a> <a title="EMJ Oncology 4.1 2016 page 127" href="http://viewer.zmags.com/publication/f4759b38?page=127"> genes involved in normal haematopoiesis.6</a> <a title="EMJ Oncology 4.1 2016 page 128" href="http://viewer.zmags.com/publication/f4759b38?page=128"> DNMT3A in MDS patients might be important p</a> <a title="EMJ Oncology 4.1 2016 page 129" href="http://viewer.zmags.com/publication/f4759b38?page=129"> 29. Cho YU et al. Preferential occurrence of spli</a> <a title="EMJ Oncology 4.1 2016 page 130" href="http://viewer.zmags.com/publication/f4759b38?page=130"> PALLIATIVE RADIOTHERAPY AND HORMONAL DEPRIVATIO</a> <a title="EMJ Oncology 4.1 2016 page 131" href="http://viewer.zmags.com/publication/f4759b38?page=131"> Some concerns have been raised about channel TURP</a> <a title="EMJ Oncology 4.1 2016 page 132" href="http://viewer.zmags.com/publication/f4759b38?page=132"> Ethical Considerations All patients provided w</a> <a title="EMJ Oncology 4.1 2016 page 133" href="http://viewer.zmags.com/publication/f4759b38?page=133"> Acknowledgements All staff working at the unit ar</a> <a title="EMJ Oncology 4.1 2016 page 134" href="http://viewer.zmags.com/publication/f4759b38?page=134"> UPCOMING EVENTS European CanCer Organisation (ECC</a> <a title="EMJ Oncology 4.1 2016 page 135" href="http://viewer.zmags.com/publication/f4759b38?page=135"> ONCOLOGY IMPAKT 2017 Breast Cancer Conference 4th</a> <a title="EMJ Oncology 4.1 2016 page 136" href="http://viewer.zmags.com/publication/f4759b38?page=136"> EUROPEAN MEDICAL JOURNAL provides influential arti</a> <a title="EMJ Oncology 4.1 2016 page 137" href="http://viewer.zmags.com/publication/f4759b38?page=137"> Buyer’s Guide • ABBVIE • ADVANCED ACCELERATO</a> <a title="EMJ Oncology 4.1 2016 page 138" href="http://viewer.zmags.com/publication/f4759b38?page=138"> SUBSCRIBE TO RECEIVE THE LATEST PUBLICATIONS, NE</a>